Manufacturing roundup: Cytiva partners with Aurisco to build site for oligonucleotides; EuroAPI investing €40M to boost production
The Chinese CDMO Aurisco is linking up with Cytiva to build a platform to produce oligonucleotides.
Dubbed the Oglio FlexFacotry platform, the companies tout the line as a faster and more efficient way to make oligonucleotides. It will be the first of three new commercial manufacturing lines that Aurisco is building in Yangzhou, China. The site will be planning to produce 200 kilograms of oligonucleotides annually.
In an email to Endpoints News, a Cytiva spokesperson said that Aurisco and Cytiva have been collaborating since 2021.
“In this new collaboration, Cytiva will offer a comprehensive enterprise solution to Aurisco. It includes an Oligo FlexFactory platform and various technical and service support, such as process design of the manufacturing site, as well as life-cycle project management,” the spokesperson said.
They added that the size of the facility would be around 2,500 square meters, with the phase one investment being in the “dozens of millions” of dollars. The facility is scheduled to be completed in the first quarter of 2024 and will hire around 100 people.
EuroAPI is placing an investment in its manufacturing site in France
The API manufacturer that spun off from Sanofi, EuroAPI, is investing in one of its facilities in France.
EuroAPI’s board approved a €40 million ($43.3 million) investment for new technology dedicated to vitamin B12 production at its manufacturing site in Saint-Aubin-lès-Elbeuf, France. The investment is designed to boost its manufacturing capacity by 2025. The investment also comes with financial support from the French government to the tune of €7.9 million ($8.5 million).
This expansion, along with other investments at this site, plans to boost production by 60% with the new technology cutting down on waste and water consumption.
“This key investment in France will enable us to increase our productivity in a dynamic vitamin B12 market, growing at 6-7% per annum. It will also increase the level of differentiation of our portfolio while implementing technology for greener production,” said Karl Rotthier, EuroAPI’s CEO, in a statement.
Viralgen gets the ok to start manufacturing at a new site in Spain
Viralgen, a member of the Bayer group, has gotten the cGMP certification to manufacture human medicinal products at its site in San Sebastian, Spain.
The approval came from the Spanish Agency for Medicines and Medical Devices, a part of the EMA network. Viralgen now has two sites in San Sebastian operating and has 300,000 square feet of space and can produce 2,000 liters of product.
The CDMO will be producing recombinant adeno-associated (rAAV) gene therapies. Viralgen is also planning to open more manufacturing and development space at the end of Q1 2023. Viralgen is also looking to expand its partnership capabilities and works with companies that are entering Phase III studies and seeking approvals for commercialization.
“Being a fully integrated CDMO, we offer a continuum of products and services, including process, analytical development, stability studies and fill and finish for all types of rAAV serotypes. This can significantly shorten the time to market, help with the predictable cost of goods and reduce the waiting time experienced by patients who have run out of options and hope for breakthrough treatments,” said Jimmy Vanhove, CEO of Viralgen, in a statement.
Lifecore Biomedical net $38M+ Series A to start the year
The Chaska, MN-based CDMO Lifecore Medical has grabbed itself some cash to start the year.
The CDMO netted $38.75 million in a private placement, it announced on Monday, selling 38,750 shares.
“We expect to use the proceeds of the investment to support both our working capital and capital expenditure requirements to deliver on our increased near- and longer-term customer demands while we focus on additional cost savings, driving free cash flow and divesting our non-CDMO assets,” said Lifecore CEO James Hall in a statement.
The private placement was led by Legion Partners and 22NW Fund with participation from Wynnefield Capital, Cove Street Partners and 325 Capital.
Sovereign Pharmaceuticals acquires Texas manufacturing facility from Monarch
Sovereign Pharmaceuticals, a subsidiary of Alora Pharmaceuticals, has purchased a manufacturing facility in Fort Worth, TX, from Monarch PCM.
The acquisition, which closed on Jan. 4, includes all of Monarch’s equipment at the site along with a leased space, which is in the same complex as Sovereign’s main facility. This move will allow Sovereign to expand its current operations once the site is renovated, and add 48 employees to Sovereign’s ranks.
Sovereign now has around 60,000 square feet of manufacturing space, bringing its total footprint to over 300,000 square feet.
“The acquisition of the Monarch assets will significantly improve our ability to manufacture solid, semi-solid and liquid manufacturing in large volumes,” according to Art Deas, CEO of Alora, in a statement.
Sai Life Sciences partners with Schrödinger to set up a research lab in India
The Indian contract research and manufacturing company Sai Life Sciences has inked a 5-year agreement with Schrödinger to establish a research laboratory in the city of Hyderabad, India.
The lab, which is being built on Sai’s R&D campus in Hyderabad, will be dedicated to researching medicinal and synthetic chemistry, in vitro biology and other chemical processes to develop candidates. Schrödinger will provide technological platforms for the lab.
The lab is scheduled to open in April of this year and staff around 75 people, with Sai actively recruiting positions.
Canadian CDMO relocating and expanding its development laboratories
The Canada-based Eurofins CDMO Alphora is relocating its active pharmaceutical ingredient development laboratories within the city limits of Mississauga, Ontario, Canada.
The 56,000-square-foot building will house Eurofins’ API R&D lab, along with its analytical services team. The new site has the capacity for several research and development processes and new office space while expanding its overall lab space.
The site is also part of the CDMO’s vision for a 14-acre campus at a nearby research park where the company plans to establish more manufacturing services, including a new plant to produce APIs, which plans to come online in the middle of this year.
Astrea Bioseparations acquires chromatography columns manufacturer
Astra Bioseparations, a producer of purification and bioseparation tech, has acquired Delta Precision for an undisclosed amount.
Delta is a manufacturer of chromatography columns that are used by pharmaceutical and biotech companies.
The move will also allow Astrea to expand its product offerings to include a “full range” of chromatography columns for biomanufacturing and add to its portfolio of resins, reusable columns and other products.
“This is a highly strategic move for us, allowing us to offer a full range of industry-leading purification and separation tools,” said Astrea Bioseparations CEO Terry Pizzie, in a statement.
WuXi STA starts up an oral solid manufacturing line close to home
WuXi AppTec subsidiary WuXi STA has started operations on a new continuous manufacturing line for oral solids at its facility in WuXi city, China.
According to the company, this new manufacturing line will provide a higher yield of oral solids as well as shortened timelines for getting to market.
Minzhang Chen, the CEO of WuXi STA, said in a statement that this line is the first continuous manufacturing line for oral solids at its site in WuXi city.